Using a new drug to help muscles recover after nerve injuries
Official title: Connexin Hemichannel Blockers to Preserve Muscle Function and Improve Recovery After Neuromuscular Trauma
Funded at Philadelphia VA Medical Center · NIH-10999266 · Data updated 2026-11-12
This study is looking at how a drug called boldine might help people who have had serious nerve or muscle injuries by preventing muscle loss and helping them recover better, which could give them more time for surgery if needed.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Philadelphia VA Medical Center NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | November 1, 2024 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01RX005045-01A1 |
| Project ID | NIH-10999266 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have suffered severe neuromuscular trauma, particularly those with peripheral nerve injuries or muscle damage.
✕Less likely to help
Patients with mild neuromuscular injuries or those who do not require surgical intervention may not benefit from this research.
What this research studies
This research focuses on patients who have experienced severe neuromuscular trauma, such as injuries to peripheral nerves or muscles. The team is investigating a drug called boldine, which blocks specific channels in cells that contribute to muscle damage after injury. By conducting studies in animal models, the researchers aim to understand how this drug can prevent muscle atrophy and promote recovery, potentially extending the time available for surgical interventions. The goal is to improve the chances of meaningful functional recovery for patients suffering from these injuries.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly enhance muscle recovery and function after neuromuscular injuries.
How similar studies have gone: While the use of connexin hemichannel blockers is a novel approach, similar strategies targeting muscle recovery after nerve injuries have shown promise in preliminary studies.
Where this research is happening
-
Philadelphia VA Medical Center
Philadelphia, United States Active
Researchers
- Principal investigator: Cullen, Daniel Kacy — Philadelphia VA Medical Center
- Study coordinator: Cullen, Daniel Kacy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.